Effect of Spirinolactone in treatment of Schizophrenia
Phase 3
Recruiting
- Conditions
- Schizophrenia.Schizophrenia
- Registration Number
- IRCT20090117001556N120
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Diagnosis of Schizophrenia based on DSM-5 criteria
Age between 18-50
Chronic Schizophrenia- duration of the disorder more than 2 years
Minimum score of 19 in negative sub score
Exclusion Criteria
Any serious medical or neurological problem
IQ less than 70
Substance dependence during the last 6 months(except for nicotine and caffeine)
Receiving ECT during the last 2 weeks
Serum potassium more than 5 meq/L
History of cardiosurgery
Receiving oral antipsychotics during the last week or long-standing antipsychotic during the last month
Meeting the criteria of major depressive disorder
Suicidality
Concurrent consumption of alcohol
Pregnant or lactating women
Receiving Pentoxifylline
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Severity of schizophrenia. Timepoint: Baseline and weeks 2- 4- 8 after beginning of treatment. Method of measurement: by Positive and Negative Symptoms Scale.
- Secondary Outcome Measures
Name Time Method Cognitive symptoms. Timepoint: Baseline and weeks 2- 4- 8 after beginning of treatment. Method of measurement: by MMSE.